The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
Open accessAbstract
To determine causes of interindividual variation in insulin requirements, we recruited 20 type 2 diabetic patients with stable glucose control and insulin doses for >1 year on combination therapy with bedtime NPH insulin and metformin. Insulin absorption (increase in free and total insulin over 8 h after a subcutaneous dose of regular insulin) and actions of intravenous (6-h 0.3 mU x kg(-1) x min(-1) euglycemic insulin clamp combined with [3-3H]glucose) and subcutaneous (glucose infusion rate required to maintain isoglycemia and suppression of free fatty acids [FFAs]) insulin, liver fat content (proton spectroscopy), visceral fat (magnetic resonance imaging), weight, and body composition were determined. We found the following variation in parameters: insulin dose range 10-176 U (mean 42 U, fold variation 17.6x) or 0.13-1.39 U/kg (0.44 U/kg, 10.7x), absorbed insulin 10.6x, action of subcutaneous insulin to suppress FFAs 7.5 x and to stimulate glucose metabolism (M value) 11.5x, body weight 67-127 kg (91 kg, 1.9x), liver fat 2-28% (12%, 14x), and visceral fat 179-2,053 ml (1,114 ml, 11.5x). The amount of insulin absorbed, measured as either free or total insulin, was significantly correlated with its ability to suppress FFAs and stimulate glucose metabolism but not with the insulin dose per se. The actions of absorbed insulin were, on the other hand, significantly correlated with the daily insulin dose (r = 0.70 for action on FFAs, P < 0.001, and r = -0.61 for M value, P < 0.005). Actions of subcutaneous and intravenous insulin to suppress FFAs were significantly correlated (r = 0.82, P < 0.001, R2 = 67%). Of the measures of adiposity, the percent hepatic fat was the parameter best correlated with the daily insulin dose (r = 0.76, P < 0.001). The percent hepatic fat was also significantly correlated with the ability of intravenous insulin to suppress endogenous glucose production (r = 0.72, P < 0.005). We conclude that the major reason for interindividual variation in insulin requirements in type 2 diabetes is the variation in insulin action. Variation in hepatic fat content may influence insulin requirements via an effect on the sensitivity of endogenous glucose production to insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies by our group (9, 17-20) and others (7, 21, 22) have demonstrated a strong relationship between triglyceride content in liver and muscle and insulin resistance in these tissues.”
From Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy (2002) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“This measurement has been validated against histologically determined lipid content 44 and against estimates of fatty degeneration or infiltration by x-ray computer-assisted tomography.38”
From Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. (2008) · cites this paper as [38]
In the citing paper
“The associations between liver fat and hepatic insulin resistance have previously been reported by Bajaj et al, 62 who studied 14 type 2 diabetic patients, and by us in nondiabetic subjects 24,39 and type 2 diabetic patients treated with insulin. 36,38”
From Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. (2008) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Desbuquois, B., & Aurbach, G. D. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-5-732 · Cited by 1,295
Lillioja, S., Young, A. A., Culter, C. L., Ivy, J. L., Abbott, W. G., Zawadzki, J. K., Yki-Järvinen, H., Christin, L., Secomb, T. W., & Bogardus, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113088 · Cited by 782
Self-citationA New and Rapid Method for the Determination of Glucose by Measurement of Rate of Oxygen Consumption
Kadish, A. H., Litle, R. L., & Sternberg, J. (1968) · Clinical Chemistry · doi:10.1093/clinchem/14.2.116 · Cited by 739
Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo
Szczepaniak, L. S., Babcock, E. E., Schick, F., Dobbins, R. L., Garg, A., Burns, D. K., McGarry, J. D., & Stein, D. T. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.5.e977 · Cited by 688
Liver Pathology and the Metabolic Syndrome X in Severe Obesity
Marceau, P., Biron, S., Hould, F. S., Marceau, S., Simard, S., Thung, S. N., & Kral, J. G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.5.5661 · Cited by 633
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., BLIX, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
Self-citationQuantification of liver fat using magnetic resonance spectroscopy
Thomsen, C., Becker, U., Winkler, K., Christoffersen, P., Jensen, M., & Henriksen, O. (1994) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(94)92543-7 · Cited by 332
A microfluorometric method for the determination of free fatty acids in plasma
Miles, J., Glasscock, R., Aikens, J., Gerich, J. E., & Haymond, M. W. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38029-9 · Cited by 329
Research works printed but not linked: 1
- Gidez LJ, Miller GJ, Burstein M, Eder HA: Analysis of plasma high density lipoprotein subclasses by a precipitation procedure: correlation with prepar- ative and analytical ultracentrifugation. In High Density Lipoprotein Method- ology Workshop, San Francisco, 1979.
Cited by
Sorted by citations
Simental‐Mendía, L. E., Rodríguez‐Morán, M., & Guerrero‐Romero, F. (2008) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0034 · Cited by 2,581
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Self-citationProgression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Seppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168
Self-citationA position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez‐Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,083
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L., Lundbom, N. M. I., Rissanen, A., Ridderstråle, M., Groop, L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.005 · Cited by 840
Self-citationKotronen, A., & Yki‐Järvinen, H. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.147538 · Cited by 793
Self-citationAdipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Overproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citationBays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800
De novo lipogenesis in health and disease
Ameer, F., Scandiuzzi, L., Hasnain, S., Kalbacher, H., & Zaidi, N. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.003 · Cited by 650
Causes and Metabolic Consequences of Fatty Liver
Stefan, N., Kantartzis, K., & Häring, H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0009 · Cited by 536
Tiikkainen, M., Häkkinen, A.-M., Korsheninnikova, E., Nyman, T., Mäkimattila, S., & Yki-Järvinen, H. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2169 · Cited by 524
Self-citationNon-alcoholic fatty liver disease and diabetes
Hazlehurst, J., Woods, C. P., Marjot, T., Cobbold, J., & Tomlinson, J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 541
Larson-Meyer, D. E., Heilbronn, L. K., Redman, L. M., Newcomer, B. R., Frisard, M. I., Anton, S., Smith, S. R., Alfonso, A., Ravussin, E., & the Pennington CALERIE Team (2006) · Diabetes Care · doi:10.2337/dc05-2565 · Cited by 504
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., & the LIDO Study Group (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12963 · Cited by 502
Taylor, R. (2013) · Diabetes Care · doi:10.2337/dc12-1805 · Cited by 485
Luukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461
Self-citationRavussin, É., & Smith, S. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04292.x · Cited by 466
Tetri, L. H., Basaranoglu, M., Brunt, E. M., Yerian, L. M., & Neuschwander-Tetri, B. A. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90272.2008 · Cited by 378
Liver Fat in the Metabolic Syndrome
Kotronen, A., Westerbacka, J., Bergholm, R., Pietiläinen, K. H., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0482 · Cited by 452
Self-citationAMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Ruderman, N., & Prentki, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1344 · Cited by 451
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
Lonardo, A., Bellentani, S., Argo, C. K., Ballestri, S., Byrne, C. D., Caldwell, S. H., Cortez‐Pinto, H., Grieco, A., Machado, M. V., Miele, L., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.08.004 · Cited by 452
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Self-citationGene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427
Self-citationKelley, D. E., McKolanis, T. M., Hegazi, R. A. F., Kuller, L. H., & Kalhan, S. C. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00117.2003 · Cited by 426
Heilbronn, L. K., Smith, S. R., & Ravussin, É. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802853 · Cited by 416
Kelley, D. E., & Goodpaster, B. H. (2001) · Diabetes Care · doi:10.2337/diacare.24.5.933 · Cited by 411
Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance
Roden, M. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0190 · Cited by 407
Diabetes Mellitus and Its Metabolic Complications: The Role of Adipose Tissues
Dilworth, L., Facey, A., & Omoruyi, F. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147644 · Cited by 445
Dietary fat content modifies liver fat in overweight nondiabetic subjects
Westerbacka, J., Lammi, K., Häkkinen, A.-M., Rissanen, A., Salminen, I., Aro, A., & Yki-Järvinen, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1983 · Cited by 379
Self-citationBajaj, M. S., Suraamornkul, S., Piper, P. K., Hardies, L. J., Glass, L. C., Cersósimo, E., Pratipanawatr, T., Miyazaki, Y., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031315 · Cited by 355
Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause
Taylor, R. (2008) · Diabetologia · doi:10.1007/s00125-008-1116-7 · Cited by 352
Kotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S., & Yki–Järvinen, H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.021 · Cited by 339
Self-citationWesterbacka, J., Corn�r, A., Tiikkainen, M., Tamminen, M., Vehkavaara, S., H�kkinen, A.-M., Fredriksson, J., & Yki-J�rvinen, H. (2004) · Diabetologia · doi:10.1007/s00125-004-1460-1 · Cited by 338
Self-citationTamura, Y., Tanaka, Y., Sato, F., Choi, J. B., Watada, H., Niwa, M., Kinoshita, J., Ooka, A., Kumashiro, N., Igarashi, Y., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1959 · Cited by 334
Non-alcoholic fatty liver disease and the metabolic syndrome: An update
Rector, R. S., Thyfault, J. P., Wei, Y., & Ibdah, J. A. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.185 · Cited by 337
Kabir, M., Catalano, K. J., Ananthnarayan, S., Kim, S. P., Van Citters, G. W., Dea, M. K., & Bergman, R. N. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00203.2004 · Cited by 327
Zelber–Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y., Santo, M., Leshno, M., Blendis, L., Halpern, Z., & Oren, R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.004 · Cited by 317
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314
Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes.
Krssak, M., Brehm, A., Bernroider, E., Anderwald, C., Nowotny, P., Man, C. D., Cobelli, C., Cline, G. W., Shulman, G. I., Waldhäusl, W., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3048 · Cited by 313
Hepatic steatosis in obese patients: clinical aspects and prognostic significance
Festi, D., Colecchia, A., Sacco, T., Bondi, M., Roda, E., & Marchesini, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00126.x · Cited by 308
Heilbronn, L. K., Rood, J. C., Janderova, L., Albu, J., Kelley, D. E., Ravussin, É., & Smith, S. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031410 · Cited by 312
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
Targher, G., & Byrne, C. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3093 · Cited by 299
Understanding the mechanisms of reversal of type 2 diabetes
Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30076-2 · Cited by 299
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition
Cave, M. C., Deaciuc, I. V., Mendez, C. M., Song, Z., Joshi‐Barve, S., Barve, S. S., & McClain, C. J. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.12.006 · Cited by 292
Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L. J., Pratipanawatr, W., Glass, L. C., Cersósimo, E., Miyazaki, Y., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1364 · Cited by 291
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Self-citationFat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’
Lundgren, M., Svensson, M. K. E., Lindmark, S., Renström, F., Ruge, T., & Eriksson, J. W. (2007) · Diabetologia · doi:10.1007/s00125-006-0572-1 · Cited by 283
Tiikkainen, M., Bergholm, R., Vehkavaara, S., Rissanen, A., Häkkinen, A.-M., Tamminen, M., Teramo, K., & Yki-Järvinen, H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.701 · Cited by 271
Self-citationIntramuscular and Liver Triglycerides Are Increased in the Elderly
Cree‐Green, M., Newcomer, B. R., Katsanos, C. S., Sheffield‐Moore, M., Chinkes, D. L., Aarsland, A. A., Urban, R. J., & Wolfe, R. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031986 · Cited by 273
Stanhope, K. L., & Havel, P. J. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f2b24a · Cited by 274
Fat in the liver and insulin resistance
Yki‐Järvinen, H. (2005) · Annals of Medicine · doi:10.1080/07853890510037383 · Cited by 269
Self-citationVirkamäki, A., Korsheninnikova, E., Seppälä‐Lindroos, A., Vehkavaara, S., Goto, T., Halavaara, J. T., Häkkinen, A., & Yki‐Järvinen, H. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2337 · Cited by 261
Self-citationLuukkonen, P. K., Dufour, S., Lyu, K., Zhang, X., Hakkarainen, A., Lehtimäki, T. E., Cline, G. W., Petersen, K. F., Shulman, G. I., & Yki‐Järvinen, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922344117 · Cited by 261
Self-citationStandardized assessment of whole body adipose tissue topography by MRI
Machann, J., Thamer, C., Schnoedt, B., Haap, M., Haring, H., Claussen, C., Stumvoll, M., Fritsche, A., & Schick, F. (2005) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.20292 · Cited by 266
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Dharmalingam, M., & Yamasandhi, P. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_585_17 · Cited by 239
Kotronen, A., Seppänen‐Laakso, T., Westerbacka, J., Kiviluoto, T. A., Arola, J. T., Ruskeepää, A., Orešič, M., & Yki‐Järvinen, H. (2008) · Diabetes · doi:10.2337/db08-1074 · Cited by 253
Self-citationNonalcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-Aged Japanese Men
Shibata, M., Kihara, Y., Taguchi, M., Tashiro, M., & Otsuki, M. (2007) · Diabetes Care · doi:10.2337/dc07-0792 · Cited by 238
McClean, P. L., Irwin, N., Cassidy, R. S., Holst, J. J., Gault, V. A., & Flatt, P. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00460.2007 · Cited by 239
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Chang, Y., Ryu, S., Sung, E., & Jang, Y. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.081257 · Cited by 227
Interaction between free fatty acids and glucose metabolism
Boden, G. H. (2002) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200209000-00014 · Cited by 224
Kirwan, J. P., Solomon, T. P. J., Wojta, D. M., Staten, M. A., & Holloszy, J. O. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00210.2009 · Cited by 218
Sevastianova, K., Santos, A., Kotronen, A., Hakkarainen, A., Makkonen, J., Silander, K., Peltonen, M., Romeo, S., Lundbom, J., Lundbom, N., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.038695 · Cited by 211
Self-citationEffect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients
Carey, D., Cowin, G., Galloway, G. J., Jones, N. P., Richards, J. C., Biswas, N., & Doddrell, D. M. (2002) · Obesity Research · doi:10.1038/oby.2002.137 · Cited by 210
Shojaee‐Moradie, F., Baynes, K., Pentecost, C., Bell, J. D., Thomas, E. L., Jackson, N. C., Stolinski, M., Whyte, M., Lovell, D., Bowes, S. B., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0498-7 · Cited by 209
Delarue, J., Foll, C. L., Corporeau, C., & Lucas, D. (2004) · annales de biologie animale biochimie biophysique · doi:10.1051/rnd:2004033 · Cited by 205
Effect of liver fat on insulin clearance
Kotronen, A., Vehkavaara, S., Seppälä-Lindroos, A., Bergholm, R., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00444.2007 · Cited by 202
Self-citationHepatic glucose metabolism in humans—its role in health and disease
Roden, M., & Bernroider, E. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(03)00031-9 · Cited by 201
Adipose tissue distribution is different in type 2 diabetes
Gallagher, D., Kelley, D. E., Yim, J., Spence, N., Albu, J., Boxt, L. M., Pi‐Sunyer, F. X., & Heshka, S. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26955 · Cited by 206
Adiels, M., Westerbacka, J., Soro‐Paavonen, A., Häkkinen, A. ‐., Vehkavaara, S., CASLAKE, M. J., Packard, C. J., Olofsson, S.-O., Yki‐Järvinen, H., Taskinen, M., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0790-1 · Cited by 197
Self-citationKotronen, A., Juurinen, L., Hakkarainen, A., Westerbacka, J., Cornér, A., Bergholm, R., & Yki-Järvinen, H. (2008) · Diabetes Care · doi:10.2337/dc07-1463 · Cited by 196
Self-citationRaubenheimer, P. J., Nyirenda, M., & Walker, B. R. (2006) · Diabetes · doi:10.2337/db06-0097 · Cited by 199
Kim, S. P., Ellmerer, M., Citters, G. W. V., & Bergman, R. N. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2453 · Cited by 195
Toledo, F. G. S., Sniderman, A. D., & Kelley, D. E. (2006) · Diabetes Care · doi:10.2337/dc06-0455 · Cited by 196
Kim, H., Haluzı́k, M., Shyr, Z. A., Yau, D., Joseph, J. W., Fernandez, A. M., Reitman, M. L., Yakar, S., STANNARD, B. S., Héron‐Milhavet, L., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1770 · Cited by 192
Sutinen, J., Häkkinen, A., Westerbacka, J., Seppälä‐Lindroos, A., Vehkavaara, S., Halavaara, J. T., Järvinen, A., Ristola, M. A., & Yki‐Järvinen, H. (2003) · Antiviral Therapy · doi:10.1177/135965350300800303 · Cited by 189
Self-citationHwang, J.-H., Stein, D. T., Barzilai, N., Cui, M.-H., Tonelli, J., Kishore, P., & Hawkins, M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00590.2006 · Cited by 188
A Promoter Genotype and Oxidative Stress Potentially Link Resistin to Human Insulin Resistance
Smith, S. R., Bai, F., Charbonneau, C., Rossmeislová, L., & Argyropoulos, G. A. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1611 · Cited by 188
Sutinen, J., Häkkinen, A.-M., Westerbacka, J., Seppälä-Lindroos, A., Vehkavaara, S., Halavaara, J., Järvinen, A., Ristola, M., & Yki-Järvinen, H. (2002) · AIDS · doi:10.1097/00002030-200211080-00011 · Cited by 184
Self-citationCussons, A. J., Watts, G. F., Mori, T. A., & Stuckey, B. G. A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0870 · Cited by 183
Matsumoto, M., Ogawa, W., Akimoto, K., Inoue, H., Miyake, K., Furukawa, K., Hayashi, Y., Iguchi, H., Matsuki, Y., Hiramatsu, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18816 · Cited by 176
Westerbacka, J., Yki‐Järvinen, H., Vehkavaara, S., Häkkinen, A., Andrew, R., Wake, D. J., Seckl, J. R., & Walker, B. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030596 · Cited by 176
Self-citationEctopic fat and cardiometabolic and vascular risk
Lim, S. K., & Meigs, J. B. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.077 · Cited by 175
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Orešič, M., Hyötyläinen, T., Kotronen, A., Gopalacharyulu, P. V., Nygrén, H., Arola, J. T., Castillo, S., Mattila, I. M., Hakkarainen, A., Borra, R., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2981-2 · Cited by 173
Self-citationAnderwald, C. H., Bernroider, E., Krššák, M., Stingl, H., Brehm, A., Bischof, M. G., Nowotny, P., Roden, M., & Waldhäusl, W. K. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3025 · Cited by 166
Hegarty, B. D., Cooney, G. J., Kraegen, E. W., & Furler, S. M. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1477 · Cited by 166
Kelley, D. E., Kuller, L. H., McKolanis, T. M., Harper, P. H., Mancino, J., & Kalhan, S. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.33 · Cited by 166
Chang, Y., Ryu, S., Sung, E., Woo, H., Oh, E., Cha, K., Jung, E., & Kim, W. S. (2008) · Metabolism · doi:10.1016/j.metabol.2007.11.022 · Cited by 164
Liver‐Fat Accumulation and Insulin Resistance in Obese Women with Previous Gestational Diabetes
Tiikkainen, M., Tamminen, M., Häkkinen, A., Bergholm, R., Vehkavaara, S., Halavaara, J. T., Teramo, K., Rissanen, A., & Yki‐Järvinen, H. (2002) · Obesity Research · doi:10.1038/oby.2002.118 · Cited by 165
Self-citation
Metadata
- Authors
- Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H.
- Affiliations
- University of Helsinki (FI)
- Department of Medicine, University of Helsinki, Finland.
- ORCID
- Goto, T
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2000-05-01
- Volume
- 49
- Issue
- 5
- Pages
- 749-758
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2132477505
- Cited by
- 431
- References
- 40
- Citations by year
- 2025: 5 · 2024: 2 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 13 · 2019: 10 · 2018: 8 · 2017: 19 · 2016: 9 · 2015: 11 · 2014: 21 · 2013: 25 · 2012: 13
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin requirement, insulin absorption, hepatic fat content, free fatty acids, insulin action, glucose metabolism, insulin resistance, visceral fat, adiposity, interindividual variability, insulin dose adjustment, metformin, NPH insulin, hepatic steatosis, hepatic insulin sensitivity, hepatic insulin secretion, hepatic insulin clearance
- MeSH terms
- Absorption, Adipose Tissue, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Fatty Acids, Nonesterified, Female, Glucose, Humans, Hypoglycemic Agents, Injections, Intravenous, Injections, Subcutaneous, Insulin, Liver, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review